Provided by Tiger Fintech (Singapore) Pte. Ltd.

F-star Therapeutics, Inc.

7.12
+0.0000
Volume:- -
Turnover:- -
Market Cap:156.51M
PE:-3.39
High:7.12
Open:7.12
Low:7.12
Close:7.12
Loading ...

Company Profile

Company Name:
F-star Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.